Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Gains from Investment Securities (2016 - 2025)

Dexcom (DXCM) has disclosed Gains from Investment Securities for 14 consecutive years, with $20.4 million as the latest value for Q4 2025.

  • Quarterly Gains from Investment Securities rose 451.35% to $20.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.8 million through Dec 2025, up 40.65% year-over-year, with the annual reading at $21.8 million for FY2025, 40.65% up from the prior year.
  • Gains from Investment Securities for Q4 2025 was $20.4 million at Dexcom, up from $900000.0 in the prior quarter.
  • The five-year high for Gains from Investment Securities was $31.8 million in Q3 2022, with the low at -$49.9 million in Q4 2021.
  • Average Gains from Investment Securities over 5 years is -$420000.0, with a median of $950000.0 recorded in 2023.
  • Peak annual rise in Gains from Investment Securities hit 875.61% in 2022, while the deepest fall reached 3040.0% in 2022.
  • Over 5 years, Gains from Investment Securities stood at -$49.9 million in 2021, then surged by 67.94% to -$16.0 million in 2022, then decreased by 27.5% to -$20.4 million in 2023, then surged by 118.14% to $3.7 million in 2024, then surged by 451.35% to $20.4 million in 2025.
  • According to Business Quant data, Gains from Investment Securities over the past three periods came in at $20.4 million, $900000.0, and -$11.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.